Crossmark

Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis

Published Online: 2018-01-10

Authors

Tornai, Tamas http://orcid.org/0000-0003-4793-9974
Tornai, David

Sipeki, Nora

Tornai, Istvan

Alsulaimani, Rayan

Fechner, Kai

Roggenbuck, Dirk http://orcid.org/0000-0002-6861-6827
Norman, Gary L. http://orcid.org/0000-0001-8992-1866
Veres, Gabor

Par, Gabriella

Par, Alajos

Szalay, Ferenc

Lakatos, Peter Laszlo

Antal-Szalmas, Peter

Papp, Maria http://orcid.org/0000-0003-3662-4010
License Information

Text and Data Mining valid from 2018-01-10

Version of Record valid from 2018-01-10
More Information

Article History

Received: 29 August 2017

Accepted: 14 December 2017

First Online: 10 January 2018

Competing Interests

: Gary L. Norman is an employee of Inova Diagnostics, an in-vitro diagnostic manufacturer. Kai Fechner is an employee of EUROIMMUN Medizinische Labordiagnostika AG, an in-vitro diagnostic manufacturer. Prof. Dr. Dirk Roggenbuck is an employee and owns shares of GA Generic Assays GmbH, an in-vitro diagnostic manufacturer.

Document is current